Clinical trials: Intestines
Fecal Incontinence, Bowel Incontinence
Fecal Incontinence Treatment (FIT) Study
Patients with severe fecal incontinence (FI), defined as two or more episodes of staining, solid or liquid FI per week, and who meet the inclusion criteria for Injection of Solesta (INJ; an inert bulking agent), or Biofeedback…
- Trial name
- NCT03811821
- Testing
- Biofeedback, Injection
- Where
- 6 sites in United States
- Volunteers
- 275 people
- Sponsor
- Mayo Clinic
Colon Cancer With Metastases to the Liver
Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab
This is a multicentre, open labeled, controlled phase study designed to assess effectiveness of chemoembolization with LC Beads, both with and without systemic chemotherapy, in the treatment of unresectable liver metastases in…
- Trial name
- DEBIRI (NCT00932438)
- Testing
- LC beads loaded with Irinotecan, Oxaliplatin, Leucovorin
- Where
- 10 sites in United States, Argentina
- Volunteers
- 70 people
- Sponsor
- University of Louisville
Crohn's Disease
Mucosal Healing Study in Crohn's Disease (CD)
The aim of the study will be to investigate the effect of certolizumab pegol on the intestinal mucosa in active Crohn's disease.
- Trial name
- MUSIC (NCT00297648)
- Testing
- Certolizumab pegol
- Where
- 19 sites in Belgium, France and 1 more
- Volunteers
- 89 people
- Sponsor
- UCB Pharma
Ulcerative Colitis
A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission
Participants who were in clinical remission on 200 milligram (mg) filgotinib once daily for at least 2 consecutive quarterly visits in the ongoing SELECTION-LTE study (GS-US-418-3899, NCT02914535), were planned to be rolled over…
- Trial name
- CAPYBARA (NCT05479058)
- Testing
- Filgotinib
- Where
- 50 sites in United States, Belgium and 11 more
- Volunteers
- 22 people
- Sponsor
- Lakefront Biotherapeutics NV
Functional Bowel Disorders
Open Label Seroquel (Quetiapine) Study for Treatment Resistant Functional Bowel Disorder
Purpose: We are proposing to examine, via open label trial, the use of Seroquel® for patients with moderate to severe functional bowel symptoms who are not receiving adequate relief from their symptoms on their present regimen of…
- Trial name
- NCT00617396
- Testing
- Quetiapine (50 mg/day-100mg/day)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of North Carolina, Chapel Hill
Ulcerative Colitis
Safety and Compliance of Taking Mesalamine Once a Day in Pediatric Patients
To determine whether once a day administration of Mesalamine is at least as safe and efficacious and administration of multiple doses a day in preventing clinical relapse of ulcerative colitis in children and adolescence.
- Trial name
- NCT00349388
- Testing
- Asacol
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Annette Langseder
Colorectal Cancer
A Study in Second Line Metastatic Colorectal Cancer
The purpose of this study is to compare overall survival in participants with metastatic colorectal cancer treated with either ramucirumab and FOLFIRI or placebo and FOLFIRI.
- Trial name
- NCT01183780
- Testing
- Ramucirumab, Irinotecan, Folinic Acid
- Where
- 213 sites in United States, Argentina and 24 more
- Volunteers
- 1,072 people
- Sponsor
- Eli Lilly and Company
Adenocarcinoma
Safety and Efficacy of Avelumab in Small Intestinal Adenocarcinoma
This is a single-agent, open label, one-arm phase 2 pilot study of avelumab in patients with advanced or metastatic adenocarcinoma of the small intestine.
- Trial name
- NCT03000179
- Testing
- Avelumab
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Short Bowel Syndrome
MENDD Tolerance Assessment Study
This study will utilize approved devices in an off-label manner to create forces required to induce intestinal lengthening. Radial and longitudinal forces are both required, and two devices will be used to create forces in order…
- Trial name
- NCT06185088
- Testing
- Coda® Balloon Catheters, Double Balloon Endoscope (DBE)
- Where
- United States
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Diabetes Mellitus
Study of Efficacy and Tolerability of Various Bowel Preps in Diabetic Patients
Poor bowel preparation and patient intolerance of the procedure are the most important factors contributing to the limitation of colonoscopy.
- Trial name
- NCT01533688
- Testing
- split dose of Golytely (polyethylene glycol electrolyte lavage solution) and bisacodyl
- Where
- United States
- Volunteers
- 212 people, healthy volunteers welcome
- Sponsor
- University of Oklahoma
Anal Cancer, Carcinoma of the Appendix
Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer
RATIONALE: Palonosetron hydrochloride may prevent nausea and vomiting caused by radiation therapy. It is not yet known whether palonosetron hydrochloride is more effective than a placebo in preventing nausea and vomiting.
- Conditions
- Anal Cancer, Carcinoma of the Appendix, Colorectal Cancer, Extrahepatic Bile Duct Cancer
- Trial name
- NCT00903396
- Testing
- palonosetron hydrochloride
- Where
- 69 sites in United States
- Volunteers
- 7 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Colorectal Cancer
Panitumumab and Irinotecan as Third-Line Therapy in Treating Patients With Metastatic Colorectal Cancer
RATIONALE: Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- PIMABI (NCT00655499)
- Testing
- Panitumumab, Irinotecan hydrochloride, Chromogenic in situ hybridization
- Where
- 9 sites in France
- Volunteers
- 65 people
- Sponsor
- GERCOR - Multidisciplinary Oncology Cooperative Group
Inflammatory Bowel Diseases, Colitis, Ulcerative
A Study to Evaluate MORF-057 in Adults With Moderately to Severely Active UC
This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 in adult patients with moderately to severely active Ulcerative Colitis (UC).
- Trial name
- EMERALD-2 (NCT05611671)
- Testing
- MORF-057
- Where
- 102 sites in United States, Australia and 19 more
- Volunteers
- 280 people
- Sponsor
- Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)
Functional Gastrointestinal Disorders, Vagus Nerve Autonomic Disorder
A Study of Randomized Sham-control Auricular TENS Unit Stimulation in Pediatric Functional Gastrointestinal Disorders
The purpose of this study is to see if using a micro-current through a device called a TENS (Transcutaneous Electrical Nerve Stimulator) unit helps to improve functional gastrointestinal disorder (FGID) symptoms in children by…
- Conditions
- Functional Gastrointestinal Disorders, Vagus Nerve Autonomic Disorder, Irritable Bowel Syndrome, Nausea
- Trial name
- NCT04247100
- Testing
- Transcutaneous Electrical Nerve Stimulation (TENS)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Gisela Grotewold Chelimsky
Irritable Bowel Syndrome, Abdominal Pain
Percutaneous Electrical Nerve Field Stimulation for Adults With Irritable Bowel Syndrome
This is a prospective, double-blind, randomized, sham-controlled pilot study evaluating the efficacy of percutaneous electrical nerve field stimulation for the treatment of adult patients with irritable bowel syndrome (IBS).
- Conditions
- Irritable Bowel Syndrome, Abdominal Pain, Autonomic Nervous System Imbalance
- Trial name
- NCT04428619
- Testing
- Peripheral Electrical Nerve Field Stimulation (PENFS) Device
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Los Angeles
Enhanced Recovery After Surgery
Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery in Subjects Undergoing Bowel Resection
This multicenter, randomized, double-blinded, placebo-controlled study will evaluate the effect of TU-100 on resolution of postoperative ileus (POI) in subjects undergoing open or laparoscopic bowel resection (BR).
- Trial name
- NCT04742907
- Testing
- TU-100
- Where
- 36 sites in United States
- Volunteers
- 402 people
- Sponsor
- Tsumura USA
Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma
Comparison of Adjuvant Chemotherapy Regimens in Treating Stage II/III Rectal Cancer
This randomized phase III trial is comparing the effectiveness of three adjuvant combination chemotherapy regimens in treating patients who are receiving radiation therapy and fluorouracil either before or after surgery for stage…
- Conditions
- Rectal Mucinous Adenocarcinoma, Rectal Signet Ring Cell Adenocarcinoma, Recurrent Rectal Carcinoma, Stage IIA Rectal Cancer AJCC v7
- Trial name
- NCT00068692
- Testing
- Radiotherapy, Fluorouracil, Leucovorin Calcium
- Where
- United States
- Volunteers
- 225 people
- Sponsor
- National Cancer Institute (NCI)
IBS - Irritable Bowel Syndrome
Irritable Bowel Syndrome and Control Volunteers: Diet Challenge
The purpose of this study is to study the relationship between the bile acids, short chain fatty acids and bacteria within the intestines.
- Trial name
- NCT03983434
- Testing
- Inulin
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Indiana University
Crohn's Disease
Efficacy and Safety of Oral OPS-2071 in Participants With Crohn's Disease Showing Symptoms of Active Inflammation
The purpose of this study is to evaluate the effects and safety of OPS-2071 (150, 300, or 600 mg twice a day [BID]) versus placebo, as add-on therapy in participants with Crohn's disease who show symptoms of active inflammation…
- Trial name
- NCT03850509
- Testing
- OPS-2071
- Where
- 31 sites in United States, Poland
- Volunteers
- 3 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Ulcerative Colitis
A Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Moderately to Severely Active Ulcerative Colitis (MK-7240-005)
The purpose of this study is to assess the safety and efficacy of tulisokibart in participants with moderately to severely active Ulcerative Colitis (UC).
- Trial name
- ARTEMIS-UC (NCT04996797)
- Testing
- Tulisokibart, Companion Diagnostic (CDx) Testing
- Where
- 88 sites in United States, Australia and 10 more
- Volunteers
- 178 people
- Sponsor
- Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.